id: NEW:aud_clinical_trial_endpoint_design_to_NEW:aud_pharmacotherapy_development
name: AUD Clinical Trial Endpoint Design â†’ AUD Pharmacotherapy Development
from_node:
  node_id: NEW:aud_clinical_trial_endpoint_design
  node_name: AUD Clinical Trial Endpoint Design
to_node:
  node_id: NEW:aud_pharmacotherapy_development
  node_name: AUD Pharmacotherapy Development
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Traditional trial endpoints focus on abstinence-based outcomes or no heavy drinking days'
- 'Step 2: Novel endpoints including WHO risk drinking level reductions allow for harm-reduction approaches'
- 'Step 3: Biological markers provide objective measurement alternatives to self-report'
- 'Step 4: Patient-oriented outcomes and NIAAA recovery definitions expand scope beyond consumption alone'
- 'Step 5: Greater breadth of endpoint utilization better captures AUD symptomatology complexity, enabling
  more effective pharmacotherapy development'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Malia A Belnap et al. 2024. "Endpoints for Pharmacotherapy Trials for Alcohol Use
    Disorder." https://doi.org/10.1007/s40290-024-00526-x
  supporting_citations:
  - World Health Organization (WHO) risk drinking level reductions framework - referenced in abstract
  - National Institute on Alcohol Abuse and Alcoholism (NIAAA) definition of recovery from AUD - referenced
    in abstract
  - Additional citations require full-text access for specific validation studies of biological markers
    and patient-oriented outcomes
  doi: 10.1007/s40290-024-00526-x
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The paper argues that expanding clinical trial endpoints from abstinence-only measures to
  include harm-reduction approaches, biological markers, and patient-centered outcomes will improve pharmacotherapy
  development for AUD.
moderators:
- name: validity_and_reliability_demonstration
  direction: strengthens
  strength: strong
  description: Novel endpoints require validity and reliability measures to be demonstrated for successful
    implementation
- name: provider_patient_experience
  direction: strengthens
  strength: moderate
  description: Patient-oriented outcomes incorporating provider-patient experiences may enhance treatment
    relevance
structural_competency:
  equity_implications: This mechanism addresses structural barriers in pharmaceutical research and development.
    The historical focus on abstinence-only endpoints reflects a moralistic rather than medical approach
    to AUD treatment that may have limited treatment development. Shifting to harm-reduction and patient-centered
    approaches acknowledges AUD as a complex medical condition requiring nuanced treatment strategies.
    This structural change in research methodology could reduce treatment disparities by validating incremental
    improvement rather than requiring complete abstinence.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.151147'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
